CalciMedica (CALC)
NASDAQ:CALC
Want to see CALC full AI Analyst Report?
CALC Stock Chart & Stats
$0.60
<$0.01(0.05%)
At close: 4:00 PM EST
$0.60
<$0.01(0.05%)
Day’s Range― - ―
52-Week Range$0.46 - $7.20
Previous CloseN/A
Volume2.29K
Average Volume (3M)71.94K
Market Cap
$9.89M
Enterprise Value$5.11M
Total Cash (Recent Filing)$8.16M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.24
Next Earnings
Aug 18, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.33
Shares Outstanding15,798,031
10 Day Avg. Volume167,963
30 Day Avg. Volume71,939
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)-14.90K
Price to Sales (P/S)0.00
P/FCF Ratio-4.66K
Enterprise Value/Market Cap0.52
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-729.48
Enterprise Value/Ebitda-0.28
Forecast
1Y Price Target
$10.00Price Target Upside1566.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.63
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
FDA No-comments Allowing KOURAGE DosingThe FDA's lack of comments after reviewing the KOURAGE protocol amendment removes the risk of a clinical hold and permits continued dosing. This preserves the trial timeline, enables ongoing safety and efficacy data collection, and supports planning for potential pivotal programs, strengthening long-term asset development.
Private Placement Up To ~$49MSecuring a private placement commitment for up to ~$49M materially extends cash runway to fund clinical operations and key trials. Structural financing support from healthcare investors reduces near-term liquidity pressure, allowing management to advance programs and de-risk value-creating milestones over the coming months.
Narrowing Losses And Reduced Reported DebtImproved net loss trajectory and elimination of reported debt in the TTM point to better expense control and lower interest exposure. Narrowing losses and reduced leverage increase financial flexibility, supporting execution of clinical programs with less immediate refinancing pressure relative to prior years.
Bears Say
Pre-revenue Business ModelCalciMedica remains pre-revenue with no product sales, meaning value is fully dependent on clinical outcomes and regulatory success. This structural absence of operating revenue forces reliance on capital markets to fund operations until commercialization, maintaining long-term execution and dilution risk for shareholders.
Persistent Heavy Cash BurnConsistent operating cash burn near -$21.2M TTM implies ongoing need for external financing to sustain trials. Even with recent financings, sustained negative FCF increases the probability of additional dilutive raises within 2–6 months, constraining strategic choices and pressuring long-term financial stability.
Negative Stockholders' EquityNegative shareholders' equity signals asset depletion and weaker balance-sheet resilience, limiting borrowing capacity and potentially triggering covenant constraints. This structural weakness raises counterparty concerns and increases dependency on dilutive financings, reducing strategic flexibility over the medium term.
CalciMedica News
CALC FAQ
What was CalciMedica’s price range in the past 12 months?
CalciMedica lowest stock price was $0.46 and its highest was $7.20 in the past 12 months.
What is CalciMedica’s market cap?
CalciMedica’s market cap is $9.89M.
When is CalciMedica’s upcoming earnings report date?
CalciMedica’s upcoming earnings report date is Aug 18, 2026 which is in 53 days.
How were CalciMedica’s earnings last quarter?
CalciMedica released its earnings results on May 12, 2026. The company reported $0.3 earnings per share for the quarter, beating the consensus estimate of -$0.28 by $0.58.
Is CalciMedica overvalued?
According to Wall Street analysts CalciMedica’s price is currently Undervalued.
Does CalciMedica pay dividends?
CalciMedica does not currently pay dividends.
What is CalciMedica’s EPS estimate?
CalciMedica’s EPS estimate is -0.26.
How many shares outstanding does CalciMedica have?
CalciMedica has 15,798,031 shares outstanding.
What happened to CalciMedica’s price movement after its last earnings report?
CalciMedica reported an EPS of $0.3 in its last earnings report, beating expectations of -$0.28. Following the earnings report the stock price went up 6.599%.
Which hedge fund is a major shareholder of CalciMedica?
Currently, no hedge funds are holding shares in CALC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CalciMedica
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.
CALC Stock 12 Month Forecast
Average Price Target
$10.00
▲(1566.67% Upside)
Technical Analysis
Ownership Overview
31.85% Insiders
1.58% Mutual Funds
1.46% Other Institutional Investors
64.54% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---